Recall of pretreatment symptoms among men treated with radiotherapy for prostate cancer

References

• Socialstyrelsen. The National board of Health and welfare. centre for Epidemiology, Cancer Incidence in Sweden 2003. Statistics Health and Diseases. 2004;10: 10(2004).
   Google Scholar
• Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 2005; 61: 415–19
   PubMed Web of Science ®Google Scholar
• Joseph J, Al-Qaisieh B, Ash D, Bottomley D, Carey B. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy. BJU Int 2004; 94: 1235–38
   PubMedGoogle Scholar
• Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Häggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781–89
   PubMed Web of Science ®Google Scholar
• Hunter KF, Moore KN, Cody DJ, Glazener CM. Conservative management for postprostatectomy urinary incontinence. The Cochrane Database of Systematic Reviews 2004; 2: CD001843
   Google Scholar
• Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet 2003; 361: 1045–53
   PubMed Web of Science ®Google Scholar
• Hunskaar S, Burgio K, Diokno A, Herzog A, Hjalmas K, Lapitan MC. Epidemiology and natural history of urinary incontinence. Incontinence: 2nd International Consultation on Incontinence2nd ed, P Abrams, L Cardozo, S Khoury, A Wein. Health Publications, Plymouth UK 2002; 165–200
   Google Scholar
• Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlén BJ, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790–96
   PubMed Web of Science ®Google Scholar
• Helgason AR, Fredrikson M, Adolfsson J, Steineck G. Decreased sexual capacity after external radiation therapy for prostate cancer impairs quality of life. Int J Radiat Oncol Biol Phys 1995; 32: 33–39
   PubMed Web of Science ®Google Scholar
• Denton A, Forbes A, Andreyev J, Maher EJ. Non surgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis. The Cochrane Database of Systematic Reviews 2002; 1: CD003455
   Google Scholar
• Litwin MS, Sadetsky N, Pasta DJ, Lubeck DP. Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. Journal of Urology 2004; 172: 515–19
   PubMedGoogle Scholar
• Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J of NCI 2004; 96: 1358–67
   PubMed Web of Science ®Google Scholar
• Fransson P, Bergstrom P, Lofroth PO, Widmark A. Prospective evaluation of urinary and intestinal side effects after BeamCath((R)) stereotactic dose-escalated radiotherapy of prostate cancer. Radiother Oncol 2002; 63: 239–48
   PubMed Web of Science ®Google Scholar
• Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61
   PubMed Web of Science ®Google Scholar
• Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 1998; 46: 473–80
   PubMed Web of Science ®Google Scholar
• Mulligan T, Moss CR. Sexuality and aging in male veterans: a cross-sectional study of interest, ability, and activity. Arch Sex Behav 1991; 20: 17–25
   PubMed Web of Science ®Google Scholar
• Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA ;277:467–471. [see comments; published erratum appears in JAMA 1997; 278: 206]
   Google Scholar
• Johansson JE, Adami HO, Andersson SO, Bergström R, Krusemo UB, Kraaz W. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet 1989; 1: 799–803
   PubMed Web of Science ®Google Scholar
• Litwin MS, McGuigan KA. Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. J Clin Oncol 1999; 17: 2882–88
   PubMed Web of Science ®Google Scholar
• Fransson P, Widmark A. Late side effects unchanged 4-8 years after radiotherapy for prostate carcinoma: a comparison with age-matched controls. Cancer 1999; 85: 678–688
   PubMed Web of Science ®Google Scholar
• Fransson P, Widmark A. Self-assessed sexual function after pelvic irradiation for prostate carcinoma. Comparison with an age-matched control group. Cancer 1996; 78: 1066–78
   PubMed Web of Science ®Google Scholar
• Herrmann D. Reporting current, past, and changed health status. What we know about distortion. Med Care 1995; 33: 89–94
   Google Scholar
• Fransson P, Damber JE, Tomic R, Modig H, Nyberg G, Widmark A. Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma. Cancer 2001; 92: 3111–19
   PubMed Web of Science ®Google Scholar
• Widmark A. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994; 74: 2520–32
   PubMed Web of Science ®Google Scholar
• Kaasa S, Bjordal K, Aaronson N, Moum T, Wist E, Hagen S, et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 1995; 31A: 2260–63
   PubMed Web of Science ®Google Scholar
• Bjordal K, Kaasa S. Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients. Acta Oncol 1992; 31: 311–21
   PubMed Web of Science ®Google Scholar
• Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 1995; 13: 1249–54
   PubMed Web of Science ®Google Scholar
• Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353–64
   PubMed Web of Science ®Google Scholar
• King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996; 5: 555–67
   PubMed Web of Science ®Google Scholar
• Fransson P, Tavelin B, Widmark A. Reliability and responsiveness of a prostate cancer questionnaire for radiotherapy-induced side effects. Support Care Cancer 2001; 9: 187–98
   PubMed Web of Science ®Google Scholar
• Cronbach LJ. Coeffecient alpha and the internal structure of tests. Psychometrika 1951; 16: 297–334
   Web of Science ®Google Scholar
• Huisman S, van Dam FS, Aaronson N, Hanewald G. On measuring complaints of cancer patients: some remarks on the time span of the questions. The Quality of Life of Cancer Patients, N Aaronson, J Beckmann. Raven Press, New York 1997; 101–09
   Google Scholar
• Breetvelt IS, van Dam FS. Underreporting by cancer patients: the case of response-shift. Soc Sci Med 1991; 32: 981–87
   PubMed Web of Science ®Google Scholar